2953 Targeted Degradation of IRAK4 Protein Via Heterobifunctional Small Molecules for Treatment of MYD88 Mutant Lymphoma Case Study
2953 Targeted Degradation of IRAK4 Protein Via Heterobifunctional Small Molecules for Treatment of MYD88 Mutant Lymphoma Case Study
1 PagesRecurrent mutations in MYD88 drive 30-40% of ABC-DLBCL; MYD88 L265P is most prevalent mutation. IRAK4 is a critical component of the Myddosome. IRAK4 catalytic and scaffolding functions are essential for full signaling to NFκB and MAPK pathways.
